Stoke Therapeutics (NASDAQ:STOK) Given New $38.00 Price Target at Cantor Fitzgerald

Stoke Therapeutics (NASDAQ:STOKGet Rating) had its target price dropped by investment analysts at Cantor Fitzgerald from $68.00 to $38.00 in a research note issued to investors on Thursday, The Fly reports. Cantor Fitzgerald’s target price would indicate a potential upside of 214.31% from the stock’s previous close.

Several other research firms also recently weighed in on STOK. Zacks Investment Research downgraded shares of Stoke Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 16th. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a research note on Monday, January 31st. They set a “buy” rating and a $50.00 target price on the stock. Finally, Bank of America reduced their target price on shares of Stoke Therapeutics from $43.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, March 16th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of “Buy” and a consensus target price of $43.17.

Shares of NASDAQ STOK opened at $12.09 on Thursday. The company’s 50-day simple moving average is $18.60 and its 200-day simple moving average is $20.34. Stoke Therapeutics has a 52-week low of $11.93 and a 52-week high of $41.60. The firm has a market cap of $473.25 million, a price-to-earnings ratio of -4.78 and a beta of 0.65.

Stoke Therapeutics (NASDAQ:STOKGet Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($1.02). Equities analysts expect that Stoke Therapeutics will post -2.86 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its position in shares of Stoke Therapeutics by 1.4% during the first quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock valued at $1,320,000 after acquiring an additional 837 shares during the last quarter. DekaBank Deutsche Girozentrale grew its holdings in shares of Stoke Therapeutics by 9.9% in the first quarter. DekaBank Deutsche Girozentrale now owns 10,000 shares of the company’s stock valued at $222,000 after purchasing an additional 900 shares in the last quarter. Ensign Peak Advisors Inc acquired a new position in shares of Stoke Therapeutics in the first quarter valued at approximately $25,000. Alliancebernstein L.P. grew its holdings in shares of Stoke Therapeutics by 6.5% in the fourth quarter. Alliancebernstein L.P. now owns 19,800 shares of the company’s stock valued at $475,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Stoke Therapeutics in the first quarter valued at approximately $27,000. Institutional investors and hedge funds own 99.87% of the company’s stock.

About Stoke Therapeutics (Get Rating)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.

Recommended Stories

The Fly logo

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.